Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.

作者: G.C. Sotiropoulos , K.W. Nowak , I. Fouzas , S. Vernadakis , S. Kykalos

DOI: 10.1016/J.TRANSPROCEED.2012.09.022

关键词:

摘要: Abstract Background With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (OLT), HCC recurrence remains the main limiting factor for long-term survival. We herein report our experience sorafenib treatment post-OLT. Patients and Methods reviewed data on transplanted receiving recurrence. Results Fourteen were included period November 2006 to February 2011. There 9 men 5 women median age 57 years. Twelve (86%) received rescue grafts through Eurotransplant allocation. Median values alpha fetoprotein levels, Model End-Stage Liver Disease score, daily dose, length 97 ng/mL, 10, 400 mg, 6.5 months, respectively. Sorafenib side effects led discontinuation ( n = 4) or reduction 2) dose. Four experienced tumor progression during treatment. Seven are currently alive, 3 died progression, 4 non–tumor-related causes death. survival was 25 months. Conclusion in transplant recipients represents a challenging oncologic approach that requires further validation prospective, multicenter studies.

参考文章(18)
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Arndt Weinmann, Ina Maria Niederle, Sandra Koch, Maria Hoppe-Lotichius, Michael Heise, Christoph Düber, Marcus Schuchmann, Gerd Otto, Peter Robert Galle, Marcus-Alexander Wörns, Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation Digestive and Liver Disease. ,vol. 44, pp. 432- 437 ,(2012) , 10.1016/J.DLD.2011.12.009
Yubao Wang, Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report World Journal of Gastroenterology. ,vol. 16, pp. 5518- 5522 ,(2010) , 10.3748/WJG.V16.I43.5518
Oliver Waidmann, Wolf-Peter Hofmann, Stefan Zeuzem, Joerg Trojan, mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation Journal of Hepatology. ,vol. 54, pp. 396- 398 ,(2011) , 10.1016/J.JHEP.2010.08.038
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo, Management of Hepatocellular Carcinoma Recurrence After Liver Transplantation Transplantation proceedings. ,vol. 42, pp. 660- 662 ,(2010) , 10.1016/J.TRANSPROCEED.2010.02.014
Sherrie Bhoori, Sara Toffanin, Carlo Sposito, Alessandro Germini, Alessandro Pellegrinelli, Andrea Lampis, Vincenzo Mazzaferro, Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle Journal of Hepatology. ,vol. 52, pp. 771- 775 ,(2010) , 10.1016/J.JHEP.2010.01.025
Carlos Gomez-Martin, Javier Bustamante, Javier F. Castroagudin, Magdalena Salcedo, Elena Garralda, Milagros Testillano, Ignacio Herrero, Ana Matilla, Bruno Sangro, Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation Liver Transplantation. ,vol. 18, pp. 45- 52 ,(2012) , 10.1002/LT.22434
Pippa Newell, Sara Toffanin, Augusto Villanueva, Derek Y. Chiang, Beatriz Minguez, Laia Cabellos, Radoslav Savic, Yujin Hoshida, Kiat Hon Lim, Pedro Melgar-Lesmes, Steven Yea, Judit Peix, Kemal Deniz, M. Isabel Fiel, Swan Thung, Clara Alsinet, Victoria Tovar, Vincenzo Mazzaferro, Jordi Bruix, Sasan Roayaie, Myron Schwartz, Scott L. Friedman, Josep M. Llovet, Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo ☆ Journal of Hepatology. ,vol. 51, pp. 725- 733 ,(2009) , 10.1016/J.JHEP.2009.03.028
Georgios C. Sotiropoulos, Nina Drühe, George Sgourakis, Ernesto P. Molmenti, Susanne Beckebaum, Hideo A. Baba, Gerald Antoch, Philip Hilgard, Arnold Radtke, Fuat H. Saner, Silvio Nadalin, Andreas Paul, Massimo Malagó, Christoph E. Broelsch, Hauke Lang, Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach? Digestive Diseases and Sciences. ,vol. 54, pp. 2264- 2273 ,(2009) , 10.1007/S10620-008-0604-4
Jeong-Ok Lee, Dae-Young Kim, Joo Han Lim, Myung-Deok Seo, Hyeon Gyu Yi, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang, Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. Journal of Gastroenterology and Hepatology. ,vol. 24, pp. 800- 805 ,(2009) , 10.1111/J.1440-1746.2008.05672.X